CagriSema vs Tirzepatide: A New Twist in the Incretin–Amylin Race: Novo Nordisk | September 2026

What Did the Study Find?

The phase III REIMAGINE 5 trial compared once-weekly CagriSema 1.0 mg/1.0 mg with tirzepatide 5 mg in adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both. Novo Nordisk

• Estimated average weight loss at week 60 was 12.4% with CagriSema vs 9.1% with tirzepatide.
• CagriSema therefore met the trial criterion for superiority in weight loss.
• HbA1c reduction was 1.71% vs 1.67%, meeting noninferiority.
• CagriSema combines cagrilintide + semaglutide, bringing amylin + GLP-1 receptor pathways together.
• Both treatments were administered once weekly.
• These remain company-reported topline phase III results, rather than a peer-reviewed full publication. Novo Nordisk

Why Does It Matter?

The result demonstrates the potential of adding amylin biology to GLP-1 therapy. But the comparator matters enormously: REIMAGINE 5 compared CagriSema 1.0/1.0 mg with tirzepatide 5 mg—not the maximum 15-mg dose. Novo Nordisk

That distinction is particularly important because the earlier REDEFINE 4 obesity trial compared higher-dose CagriSema 2.4/2.4 mg against tirzepatide 15 mg, and CagriSema failed its prespecified noninferiority endpoint despite achieving 23% weight loss. Novo Nordisk

GastroAGI Takeaway

The headline is not “CagriSema beats tirzepatide.” It is that CagriSema 1.0/1.0 mg produced greater weight loss than tirzepatide 5 mg in this specific T2D population.

The emerging obesity/metabolic-treatment question is becoming more sophisticated: which mechanism, at which dose, for which phenotype? GLP-1/GIP and GLP-1/amylin combinations may ultimately occupy different therapeutic niches rather than producing a single universal winner.